The 10 most recent market catalysts affecting $EVT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 19, 2026
Corporate Catalyst
Bullish
Impact 65
Evotec and Bristol Myers Squibb Receive FDA Acceptance for Second Drug Candidate
Evotec and Bristol Myers Squibb announced the FDA's acceptance of a second IND application for a cereblon E3 ligase modulator (CELMoD) drug candidate, which is slated to begin Phas…
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 55
Evotec Secures $2.9 Million Grant from Gates Foundation
Evotec has secured a $2.9 million grant from the Gates Foundation, extending a project focused on advanced drug safety assessment for an additional three years. This funding is sig…
Nov 13, 2026
Corporate Catalyst
Neutral
Impact 55
Evotec SE Receives Notification of Major Voting Rights Holdings
Evotec SE has reported that The Goldman Sachs Group, Inc. now holds 8.60% of its voting rights, a significant stake that crossed the disclosure threshold on November 5, 2026. This …
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 55
Evotec SE Receives Notification of Major Voting Rights Holdings from The Goldman Sachs Group, Inc.
The filing indicates that The Goldman Sachs Group, Inc. has crossed a major voting rights threshold in Evotec SE, as reported under German Securities Trading Act. This means Goldma…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 75
Evotec SE Reports Third Quarter and Nine-Month 2026 Results
Evotec SE reported its Q3 and nine-month 2026 financial results, which is a routine disclosure. However, the significant aspect is the 'slight adjustment and postponement of its mi…
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 55
JPMorgan Chase Crosses Voting-Rights Threshold in Evotec SE
Evotec SE disclosed that JPMorgan Chase crossed a voting-rights threshold on October 23, 2026, with the public notification on October 29. This event signifies a notable change in …
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 55
Evotec shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $4 price target.
The reiterated 'Buy' rating and maintained price target from HC Wainwright & Co. acts as a positive corporate catalyst for Evotec. While not new information, it reinforces analyst …
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 85
Evotec shares are trading lower after the company reported worse-than-expected Q2 financial results.
Evotec's poor Q2 results are a direct corporate catalyst, leading to a significant negative impact on its stock price. This underperformance raises concerns about the company's ope…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 85
Evotec shares are trading lower after the company announced preliminary Q2 financial results and updated its full-year 2026 outlook.
The announcement of preliminary Q2 financial results and an updated full-year 2026 outlook is a direct corporate catalyst for Evotec. The 'trading lower' indicates that the market …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.